Literature DB >> 29733806

Exploiting methionine restriction for cancer treatment.

Sushma Chaturvedi1, Robert M Hoffman2, Joseph R Bertino3.   

Abstract

Normal cells can synthesize sufficient methionine for growth requirements from homocysteine and 5-methyltetrahydrofolate and vitamin B12. However, many cancer-cell types require exogenous methionine for survival and therefore methionine restriction is a promising avenue for treatment. While the lack of the methionine salvage enzyme methylthioadenosine phosphorylase (MTAP) deficiency is associated with methionine dependence in cancer cells, there are other causes for tumors to require exogenous methionine. In this review we describe studies that show restricting methionine to certain cancers by diet or by enzyme depletion, alone or in combination with certain chemotherapeutics is a promising antitumor strategy. The basis for methionine dependence in tumor cells is also briefly reviewed.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-Methyltetrahydrofolate; MTAP; Methioninase; Methionine; Methionine restriction; Vitamin B12

Mesh:

Substances:

Year:  2018        PMID: 29733806     DOI: 10.1016/j.bcp.2018.05.003

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

Review 1.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

2.  Methionine synthase is essential for cancer cell proliferation in physiological folate environments.

Authors:  Mark R Sullivan; Alicia M Darnell; Montana F Reilly; Tenzin Kunchok; Lena Joesch-Cohen; Daniel Rosenberg; Ahmed Ali; Matthew G Rees; Jennifer A Roth; Caroline A Lewis; Matthew G Vander Heiden
Journal:  Nat Metab       Date:  2021-11-18

3.  Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.

Authors:  Dmitry Malin; Yoonkyu Lee; Olga Chepikova; Elena Strekalova; Alexis Carlson; Vincent L Cryns
Journal:  Breast Cancer Res Treat       Date:  2021-09-22       Impact factor: 4.872

4.  Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines.

Authors:  Yasmine A Hassan; Maged W Helmy; Asser I Ghoneim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-20       Impact factor: 3.195

5.  NRF2 mediates melanoma addiction to GCDH by modulating apoptotic signalling.

Authors:  Sachin Verma; David Crawford; Ali Khateb; Yongmei Feng; Eduard Sergienko; Gaurav Pathria; Chen-Ting Ma; Steven H Olson; David Scott; Rabi Murad; Eytan Ruppin; Michael Jackson; Ze'ev A Ronai
Journal:  Nat Cell Biol       Date:  2022-09-01       Impact factor: 28.213

Review 6.  Targeting the methionine addiction of cancer.

Authors:  Joni C Sedillo; Vincent L Cryns
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 7.  Glioblastoma and Methionine Addiction.

Authors:  Mark L Sowers; Lawrence C Sowers
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

8.  Methionine restriction activates the integrated stress response in triple-negative breast cancer cells by a GCN2- and PERK-independent mechanism.

Authors:  Sai Harisha Rajanala; Rachel Ringquist; Vincent L Cryns
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

Review 9.  Polyamine metabolism and cancer: treatments, challenges and opportunities.

Authors:  Robert A Casero; Tracy Murray Stewart; Anthony E Pegg
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

10.  PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.

Authors:  Marcella Barbarino; Daniele Cesari; Maria Bottaro; Luca Luzzi; Asadoor Namagerdi; Franca Maria Bertolino; Cristiana Bellan; Fabrizio Proietti; Pasquale Somma; Mariacarolina Micheli; Maria Margherita de Santi; Raffaella Guazzo; Luciano Mutti; Luigi Pirtoli; Piero Paladini; Paola Indovina; Antonio Giordano
Journal:  J Cell Mol Med       Date:  2020-04-17       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.